| Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. | |
| | |
MedLine Citation:
|
PMID: 21068204 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Smokeless, spitless tobacco products are being introduced and marketed as cigarette substitutes. Data are needed regarding how smokers interested in cessation would use these products, the levels of resultant toxicant exposure, and the feasibility of using these products as aids for tobacco cessation. METHODS: Smokers were randomized to receive Camel Snus (n = 51), Taboka (n = 52), or medicinal nicotine (n = 27) and required to quit smoking for 4 weeks. Measures of toxicant exposure and symptoms of craving and withdrawal were assessed prior to and during product use. RESULTS: Concentrations of exhaled carbon monoxide, urinary cotinine, urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its glucuronides (total NNAL), and urinary N'-nitrosonornicotine and its glucuronide (total NNN) were significantly (P values <0.05) lower at the end of treatment in each group except for total NNN in those receiving Camel Snus (P = 0.066). A significant group × time effect was observed for total NNAL concentrations (P = 0.002) with the decrease greatest in the medicinal nicotine group and smallest decrease in the Camel Snus group. No significant differences between groups were found in craving and withdrawal symptoms. CONCLUSIONS: Enrolling smokers into a cessation study utilizing newer smokeless tobacco products is feasible. Camel Snus and Taboka use was not found to be superior to medicinal nicotine in reducing withdrawal symptoms but decreases in NNAL were smaller in users of Camel Snus. IMPACT: This study demonstrates the feasibility of conducting a smoking cessation study utilizing these newer tobacco products. An appropriately powered study is needed to assess smoking cessation rates using these newer products compared with established, safer products such as medicinal nicotine. |
| | |
Authors:
|
Michael Kotlyar; Louise A Hertsgaard; Bruce R Lindgren; Joni A Jensen; Steven G Carmella; Irina Stepanov; Sharon E Murphy; Stephen S Hecht; Dorothy K Hatsukami |
Related Documents
:
|
2759604 - Ayre v aylesbury cervical spatulas. 8644834 - Grip strength and finger dexterity across five styles of commercial wrist orthoses. 18271334 - The impact of multi-skilled staff availability on day surgery cancellations. 4583184 - Double-blind cross-over study of ketoprofen and ibuprofen in management of rheumatoid a... 3992384 - Sorting out triage in urban disasters. 8855604 - Lafayette's family practice residency program: practice patterns of graduates. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural Date: 2010-11-10 |
Journal Detail:
|
Title: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology Volume: 20 ISSN: 1538-7755 ISO Abbreviation: Cancer Epidemiol. Biomarkers Prev. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-01-07 Completed Date: 2011-06-01 Revised Date: 2012-01-04 |
Medline Journal Info:
|
Nlm Unique ID: 9200608 Medline TA: Cancer Epidemiol Biomarkers Prev Country: United States |
Other Details:
|
Languages: eng Pagination: 91-100 Citation Subset: IM |
Copyright Information:
|
©2011 AACR. |
Affiliation:
|
University of Minnesota Tobacco Use Research Center, University of Minnesota, Minneapolis, Minnesota, USA. |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT00469079 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Carbon Monoxide / metabolism Cotinine / urine Feasibility Studies Humans Middle Aged Nicotine / administration & dosage* Nitrosamines / metabolism Pyridines / metabolism Smoking / drug therapy*, metabolism*, urine Smoking Cessation / methods* Substance Withdrawal Syndrome / etiology, metabolism Tobacco, Smokeless* Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
K23DA017307/DA/NIDA NIH HHS; P50 DA01333/DA/NIDA NIH HHS; P50 DA013333-10/DA/NIDA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-ol; 0/Nitrosamines; 0/Pyridines; 486-56-6/Cotinine; 54-11-5/Nicotine; 630-08-0/Carbon Monoxide; 64091-91-4/4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone |
| Comments/Corrections | |
Erratum In:
|
Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1048 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Genetic variation in the TGF-? signaling pathway and colon and rectal cancer risk.
Next Document: Functional study on a novel missense mutation of the transcription factor FOXL2 causes blepharophimo...